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Abstract
Hypertension is a major risk factor for cardiovascular and cerebrovascular 
diseases, causing high numbers of deaths and /or disabilities worldwide. Previous 
studies have reported numerous biomolecules, such as, triglycerides and fibrinogen 
as biomarkers of hypertension (HTN), but none of these biomolecules could be 
considered as ‘true’ predictive biomarkers as they were produced after the establish-
ment of HTN. Therefore, there is an urgent need for identifying and monitoring 
molecules that are linked to early pre-HTN stages, that is, prior to the onset of 
HTN. Astrocytes are the most abundant cells in the nervous system and through 
their long processes, astrocytes can communicate with both neuronal and non-
neuronal cells such as endothelial cells lining blood vessels. Thus, any biochemical 
changes in astrocytes will affect both blood vessels and neurons. We are using 
human fetal astrocytes (HFAs) to investigate the molecules which may possibly act 
as early predictive biomarkers for hypertension. Astrocytic processes are mostly 
supported by the intermediate filaments, an example is the glial fibrillary acidic 
protein (GFAP) which is a type III intermediate filament. Elevated GFAP levels 
are being considered as a marker of astroglial injury, indicating the conversion of 
non-reactive (A2) into reactive (A1) astrocytes. Our initial immunohistochemistry 
studies using anti-GFAP antibodies on astrocytes from spontaneous hypertensive 
rats (SHRs) and their normal counter parts (WKY) rats showed a similar profile to 
that of reactive (A1) and non-reactive (A2) HFAs, respectively. Numerous studies 
point to a significant role of calcium ion channel proteins in hypertension, and 
calcium channel blockers such as Amlodipine (Norvasc) Diltiazem (Cardizem) are 
commonly used as antihypertensive drugs. By using liquid chromatography–tan-
dem mass spectrometry (LC–MS/MS) we observed that reactive (A1) astrocytes, 
contain more calcium-activated proteins such as calpain, calpastatin, cathepsin and 
mitogen activated protein kinase (MAPK) as compare to normal (A2) HFAs, sug-
gesting their possible link to the future onset of HTN. Hence these proteins could be 
considered as potential early predictive biomarkers of HTN.
Keywords: Hypertension, spontaneous hypertensive rats (SHRs), WKY rats,  
Human fetal astrocytes (HFAs), Reactive (A1) and non-reactive (A2) HFAs,  
glial fibrillary acidic protein (GFAP), Ca2+ dependent proteins, LC–MS/MS technique
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1. Introduction
Scientific studies have established that prevalence of hypertension (HTN) 
needs to be reduced in order to control cardiovascular and cerebrovascular diseases 
[1]. At present, many laboratories around the world are exploring a plethora of 
biomarkers, as early indicators of HTN [2, 3], i.e., triglycerides, C-reactive protein, 
fibrinogen, serum albumin, uric acid, homocysteine and intracellular adhesion 
molecule-1(ICAM-1) [4]. All these biomarkers for hypertension are produced as 
a result of chronic disease-related comorbidities such as atherosclerosis, Type 2 
diabetes and renal failure, therefore, they cannot be considered as ‘true’ predictive 
biomarkers for hypertension. Hence, this study is focusing on glial fibrillary acidic 
protein (GFAP), and a group of calcium-dependent proteases, such as calpain, 
calpastatin, cathepsin and mitogen activated protein kinase (MAPK), known to be 
strongly associated with HTN; hence could be potential early biomarkers for HTN.
Similarly, an endogenous chemical, N-Methyl-D-Aspartic acid (NMDA), a type 
of glutamate is also documented as linked with HTN [5]. NMDA is a major excit-
atory neurotransmitter in the central nervous system, consisting of two types of 
receptors namely synaptic and extrasynaptic. Research indicates that the activation 
of the synaptic NMDA receptors is neuroprotective; whereas, the stimulation of 
extrasynaptic NMDA receptors (NMDARs) promotes cell death [6] and resultant 
HTN, which can be regulated by NMDA antagonists, such as 1-amino cyclo propane 
carboxylic acid (ACPC) [7]. NMDA type glutamate receptors are not only present 
in the neuronal cells but also in the non-neuronal cells such as astrocytes [8]. Recent 
studies have demonstrated a significant role of astrocytes in regulating blood flow 
due to the elevation in intracellular calcium (Ca2+) [9], which plays a significant 
role in the regulation of blood pressure.
Astrocytes are present between blood vessels and neurons and are responsible 
for changes in the arterial blood pressure [10]. A decline in the cerebral blood 
supply activates the astrocytes to release a chemical signal to the nearby neurons 
that raises blood pressure, restoring blood flow and oxygen supply to the brain [10]. 
Thus, astrocytes perform a balancing role between brain perfusion and neuronal 
activities by mobilising their internal calcium [11], which in turn triggers the release 
of chemical transmitters such as glutamate [12]. Consequently, there is a calcium-
dependent bidirectional signalling pathway between astrocytes and neurons [13], 
which opens up the possibility of astrocytic involvement in the modulation of 
calcium-dependent molecules such as calpain, calpastatin, cathepsin and MAPK, 
which can potentially be considered as direct predictive biomarkers of HTN.
Certain behavioural conditions, such as, stress also elevates blood pressure. 
Under stressful conditions, excessive release of corticotropin-releasing hormone 
(CRH) activates NMDA receptors, resulting in an influx of Ca2+ molecules, which 
enhance the activity of m-calpain [14]. Calpain is one of the major calcium-depen-
dent proteolytic enzymes with various isoforms such as μ-calpain and m-calpain, 
which are activated by the synaptic and extra-synaptic NMDA receptors respec-
tively [15, 16]. Studies have indicated that the activation of μ-calpain is important 
for cell-survival, whereas the stimulation of m-calpain initiates toxic effects and cell 
death [6], due to its interaction with NMDAR [17]. Activation of the type of NMDA 
receptor defines the communication from the synapse to the nucleus [18].
Stimulation of synaptic NMDAR phosphorylates the intermediate filament pro-
teins by extracellular signal regulated kinases 1 and 2 (ERK1/2) [19]. However, the 
activation of extrasynaptic NMDAR fails to phosphorylate and translocate inter-
mediate filament proteins into the nucleus. The phosphorylated or non-phosphor-
ylated state of intermediate filament proteins determine whether it promotes cell 
survival or induces cell death. These diverse functions that require the regulation 
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of gene and synapse-to-nucleus communications are controlled by nuclear calcium 
signalling [20]. Overexpression of these proteins induces neurodegeneration, 
whereas, its suppression has the opposite effect, therefore, the molecules that keep 
the balance may act as therapeutic targets for HTN.
To date, most proteomic research, targeted at discovering biomarkers, has failed 
to incorporate adequate biomarker validation studies in independent sample sets. 
These are necessary steps in the translation of potential biomarkers into clinical 
practice. Recent development of sophisticated mass spectrometry-based quantita-
tion of multiple proteins has enabled the validation of candidate biomarkers in 
different biological materials, such as astrocytes.
The literature indicates that reactive astrocytes (A1) and their intermediate fila-
ments contain greater concentrations of glial fibrillary acidic protein (GFAP) [21], 
compared to normal astrocytes (A2). The purpose of this study was, to identify and 
quantify the differences between the proteins of interest, present in the reactive 
and the normal human foetal astrocytes (HFAs), using immunocytochemistry and 
single-pot, solid-phase-enhanced sample-preparation (SP3) [22] proteomic tech-
niques. We aim to detect the immunocytochemical differences between the A1 and 
A2 HFAs using GFAP antibodies and to identify a panel of protein biomarkers in A1 
and A2 HFAs for the prediction of hypertension.
2. Materials and methods
2.1 Ethical approval
HFAs were obtained from the Biobank of Macquarie University, after approval 
from the UTS Human Research Ethics Committee (ETH17–1883).
2.2 Protocol for the cell culture of primary HFAs
After getting a material transfer agreement (MTA # 17/979) between the two 
universities, the HFAs were tested for mycoplasma contamination and were found 
to be negative. The HFAs were then cultured in T75 flasks using Roswell Park 
Memorial Institute (RPMI 1640) media containing 10% heat-inactivated foetal 
calf serum (FCS) (Table 1), at 37°C, in a 5% CO2 humidified incubator. Freshly 
prepared media was used to feed the cells every five days.
The HFAs were seeded at 4x107 cells/T75-cm2 in tissue culture flasks containing 
RPMI (4.5 g/L glucose, L-glutamine, and 25 mM HEPES buffer), plus 10% FCS at 
37°C, and incubated in a 5% CO2 humidified incubator.
For re-seeding, HFAs were detached from the flask by using 4 ml of trypsin, 
incubated for 3 minutes at 37°C, in a 5% CO2 humidified incubator. After incubation 
with trypsin, the cells were transferred to a 15 ml falcon tube and were centrifuged at 
1600 g rpm, for 3 minutes. Trypsin was removed by washing three times with phos-
phate buffered saline (PBS). The cells were then resuspended in 2 ml of fresh media 
by gentle mixing and 1 ml of this cell solution was added to each T75 flask with 14 ml 
RPMI, labelled as A1 and A2 for reactive and normal astrocytes, respectively.
2.3 Conversion of normal HFAs (A2) into reactive HFAs (A1)
After achieving 95 to 100% confluency and three days before the proteomics 
experiment, the HFAs were incubated in the RPMI media with 1% FCS instead of 
10% FCS, to avoid false positive proteomic results due to the proteins present in 
the 10% FCS. Twenty-four hours before the pellet formation for SP3 [22] protocol, 
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the cells were returned to RPMI media +10% FCS in both A1 and A2 flasks. Then, 
100 μl of 1 mM adenosine triphosphate (ATP) was added to the A1 flask to convert 
the normal HFAs into reactive HFAs [23]. After 24 hours of incubation at 37°C, in a 
5% CO2 humidified incubator, the cells were washed three times with PBS. The cells 
were subsequently detached from both flasks by adding 4 ml of trypsin and were 
incubated at 37°C in a humidified incubator, for 3 minutes. After incubation, the 
cells were transferred into two falcon tubes (15 ml tubes, labelled as A1 and A2) and 
were centrifuged at 1600 g rpm for 3 minutes. Trypsin was removed from the tubes 
by washing three times with 3 ml PBS. The cell samples from both tubes were trans-
ferred into 2 ml Eppendorf tubes and were microfuged for 1 minute, to remove PBS. 
Subsequently, the Eppendorf tubes containing cell pellets were snap frozen in liquid 
nitrogen and stored at -80°C for the proteomics experiment, using SP3 protocol.
2.4 Immunocytochemistry of HFAs using anti-GFAP stain
Six poly-L-lysine coated coverslips, three labelled as A1 and three as A2 were 
placed in a six well plate, containing 2 ml of fresh RPMI media with 10% FCS. The 
plates were incubated at 37°C, in a 5% CO2 humidified incubator to grow until 
~70% confluency was achieved.
The cells in three of the six wells, were treated with 1 mM ATP to convert them 
into reactive (A1) astrocytes, whereas the other three coverslips with the HFAs (A2) 
were not treated with ATP. After 24 hours of incubation all the cells were washed 
three times with 0.1 M PBS, fixative (4% paraformaldehyde in PBS, 7.4 pH) was 
then added for 30 minutes, at room temperature. After fixation, both types of HFAs 
were gently washed three times with PBS and were ready for permeabilization and 
blocking of the unspecific binding of the proteins. To improve the permeabiliza-
tion of the antibodies, the HFAs were incubated with 100 μl of 0.1% Triton X 100, 
for 30 minutes, at 37°C, in a 5% CO2 humidified incubator. The cells were gently 
washed three times with PBS, before being treated with the blocking solution 
(100 μl of 5% goat serum) and then the cells were incubated for 30 minutes.
S. N. Chemical Catalogue 
number
Company Amount used Quantity 
T75 flask
1 RPMI 1640 11875 Thermo 
Fisher
Scientific
45 ml 15 ml of 
complete 
media





















6 Paraformaldehyde 30525–89-4 Sigma- 
Aldrich
4% paraformaldehyde 
in PBS, with 7.4 pH
1 ml
Table 1. 
Chemicals used for the tissue culture experiments.
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The cells were incubated with a primary anti-GFAP antibody (1:100 dilution, 
ab7260 from ABCAM) at 4°C for 18 hours. Then, the HFAs were washed three times 
with PBS, and were incubated with the secondary antibody (1:100, ab150077 with 
AF488, ABCAM) in 1% BSA for 1 hour at the room temperature in the dark.
2.4.1 Nuclear staining and mounting
The HFAs were rinsed with PBS and were incubated with 1 μg/ml of nuclear 
stain [4, 6-diamidino-2-phenylindole (DAPI)] for 10 minutes followed by three 
rinses with PBS. Excess PBS was carefully wiped around the coverslips and the cells 
were mounted on the glass slides (75 mm x 25 mm and 1 mm thickness), which were 
clearly labelled with the type of cell and stain. Then a drop of mounting medium, 
Fluoroshield (ABCAM) was placed in the middle of the slide. The coverslip with the 
stained cells was carefully lifted using forceps and was placed in an inverted posi-
tion on top of the slide, air bubbles were removed, and the cells were sealed with a 
clear nail polish to prevent drying and movement under the microscope. The cells 
were stored in the dark, at +4°C till image analysis was performed using the NIKON 
A1 confocal microscope.
2.5  Protein extraction and digestion using single-pot, solid-phase-enhanced 
sample-preparation (SP3) protocol
The proteins of interest were extracted from A1 and A2 HFAs using the SP3 
protocol, before performing mass spectrometric analysis. All the chemicals and 
equipment used for the preparation of lysis buffer and for protein extraction and 
digestion using SP3 protocol are shown in Table 2 and Figure 1.
Chemical name Company Cat. No.
Bovine serum albumin (BSA) Sigma 00A2153
Sodium dodecyl sulfate (SDS) Bio-Rad 1610302
Triton X-100 Sigma T8787
Nonidet-P40 (NP-40) Merck-Millipore 492016-100ML
Tween 20 Sigma P1379
Deoxycholate Sigma 3970
Sodium chloride (NaCl) Sigma S7653
Glycerol Sigma G5516
HEPES sodium salt Sigma H3375
Iodoacetamide Bio-Rad 1632109
Dithiothreitol (DTT) Bio-Rad 1610611
Ammonium bicarbonate Sigma A6141
Trypsin + rLysC mix Promega V5073
1.5-mL Safe-Lock tubes Eppendorf 22363204
Tris-2-carboxyethyl phosphine Sigma 51805–45-9
Sera-Mag Speed Beads GE Healthcare 45152105050250
Magnetic rack, Magnetic Sphere Promega Z5342
Table 2. 
Reagents and equipment used for SP3 protocol.
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2.5.1 Preparation of reconstitution (lysis) buffer for SP3
Reconstitution buffer was freshly prepared by mixing 100 μl of each of the fol-
lowing chemicals, i.e., 10% SDS, 10% Triton x-100, 10% NP-40, 10% Deoxycholate 
and 10% Glycerol. In addition, 10 μl of 5 M NaCl, 20 μl of HEPES (pH 8.0) and 
470 μl of water was added to the mixture.
2.5.2 Extraction of the proteins from A1 and A2 HFA samples
Eppendorf tubes containing pellets of A1 and A2 astrocytes were removed from 
−80°C and were resuspended in 50 μl of lysis buffer. To facilitate the extraction 
process, the tubes were heated to 90°C on the heating block for 10 minutes. To 
reduce the number of disulfide bonds, 1 μl Tris 2-carboxyethyl phosphine (TCEP) 
was added to the samples, followed by 1 μl of acrylamide monomer to alkylate the 
mixture. After an hour of incubation at room temperature, the alkylation reaction 
was stopped by adding 1 μl of dithiothreitol (DTT). Before extracting the proteins 
from both types of HFAs, a standard curve was constructed using an ampule of 
2 mg/ml bovine serum albumin (BSA).
2.5.3 Construction of the standard curve
The standard curve was constructed using a 96 well microplate, and bovine 
serum albumin (BSA) was added at a concentration ranging from 0 to 2000 μg/ml 
diluted with double distilled water. Similarly, A1 and A2 sample solutions were also 
diluted with double distilled water at a ratio of 1:10 & 1:20. Working solution of BCA 
was prepared by adding reagent B (cupric sulfate) with reagent A (cuprous sulfate), 
at a ratio of 1:50. The plates were prepared according to Table 3. Nine wells of the 
plate were filled with 25 μl of BSA solution ranging from 0 to 2000 μg/ml along with 
the blank and two dilutions of A1 and A2 samples. Then 200 μl of working solution 
was added in each of the fourteen wells. The plates were covered with parafilm and 
were incubated at 37°C for 30 minutes, and the plates were read on the Tecan Infinite 
200 Pro, spectrophotometer, at a wavelength of 562 nm, using Magellan software.
Figure 1. 
The magnetic rack used for placing the sample-vials containing magnetic beads. When vials are placed on the 
magnetic rack, the beads start to stick to the wall of the vial. This process allows the protein molecules to attach 
safely to the beads, so unwanted fluid could be easily discarded.
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Data obtained was used to plot a standard curve and the concentration of the 
proteins in the A1 and A2 astrocyte samples were determined from Figure 2.
2.5.4 Reconstitution of the proteins from A1 and A2 samples
The cell-solution was diluted to a final volume of 48 μl by adding double dis-
tilled water and 2 μl of hydrophilic magnetic beads to the samples, giving a total 
volume of 50 μl of protein solution. Proteins were bonded with the beads by adding 
50 μl of 100% ethanol to the above mixture and vortexed for 5 minutes. Hydrophilic 
magnetic beads, were coated with carboxylate functional groups to capture the pro-
teins, making it easier to wash the cells in 100% ethanol. Surfactant was removed by 
rinsing the cells three times with 80% ethanol and the supernatant with unbound 
S.N. Vial volume of diluent (μl) Volume and source of BSA (μl) BSA concentration (μg/ml)
A 0 300 of Stock 2000
B 125 375 of Stock 1500
C 325 325 of Stock 1000
D 175 175 of vial B dilution 750
E 325 325 of vial C dilution 500
F 325 325 of vial E dilution 250
G 325 325 of vial F dilution 125
H 400 100 of vial G dilution 25
I 400 0 Blank
Samples
A1(1:10) 9 1 38
A1(1:20) 19 1 26
A2(1:10) 9 1 22
A2(1:20) 19 1 18
Table 3. 
Dilution scheme protocol for standard in vials (work-range, 25–2000 μg/mL).
Figure 2. 
BCA (Bicinchoninic acid) protein assay was used to plot standard curve for quantitation of the protein 
concentrations in the A1 and A2 astrocytes.
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compounds was discarded in a waste container. Proteins were extracted in aqueous 
solution by adding 100 μl of 200 mM ammonium bicarbonate to the protein bonded 
beads. Trypsinisation of proteins was achieved by incubating the samples overnight 
with 1 μl of trypsin at 37°C.
2.5.5 STop and go extraction (STAGE) tips protocol
Further desalting and cleaning of the peptides was performed by an extended 
protocol called STop and Go Extraction (STAGE) tips protocol [22]. The first step 
was to prepare Styrenedivinylbenzene-reverse phase sulfonated (SDB-RPS) for the 
process of solid phase extraction. Briefly, a large sized SDB-RPS disk was placed in 
a covered petri dish and from that a 47 mm disk core was used in this protocol as a 
solid phase extraction sorbent. These sorbents have a high affinity for polar organic 
compounds, and hence reduce the extraction time and solvent, used for analytical 
preparation of aqueous environmental samples.
2.5.6 Construction of STAGE tip and preparing of collection tubes
STAGE tip (Figure 3) was prepared by using a flat-ended needle, to push the 
47 mm SDB-RPS core carefully inside a 2 ml pipette-tip, keeping it 2–3 mm above 
its end. A hole was made in the middle of the lid of a 2 ml Eppendorf tube using 
a rotary cutting tool. The pipette tip with SDB-RPS disk was inserted into the 
Eppendorf tube through the hole. Double distilled water was used to make 10% v/v 
trifluoroacetic acid (TFA), then 90% of isopropanol was added to make 1% TFA 
and this was diluted 1:10 with water. Fresh elution solvent was made by mixing 
700 μl of Acetonitrile, 71 μl of NH4OH stock and 229 μl of water.
2.5.7 Desalting and washing the samples
The sample was acidified by adding 10 μl of 10% TFA and was centrifuged for 
5 minutes at maximum speed. Using one STAGE tip, the sample was pipetted into the 
top of the tip and centrifuged at 5000 g rpm for 1 minute. The tubes were repeatedly 
centrifuged until all the liquid passed through the STAGE tip. To wash the sample, 
60 μl of 1% TFA was pipetted into the STAGE tip and centrifuged at 5000 g rpm for 
2 minutes. Tubes were centrifuged three times to clear all the salts and contaminants 
from the bound peptides and the liquid in the collection tube was discarded.
2.5.8 Setting up STAGE tip in autovial insert and elution of peptides
For each sample, a separate autovial was used and a yellow spacer was placed 
between the STAGE tip and the collection tube to hold the STAGE tip in the center 
of the autovial. Elution solvent was prepared by mixing 30 ml of 1 M Ammonium 
Hydroxide with 70 ml Acetonitrile. To complete the reaction, 60 μl of elution 
solvent was pipetted into the STAGE tip and was microfuged for a few seconds to 
drag the liquid onto the disk, which was incubated on the bench for 10 minutes. 
The STAGE tip was placed in the insert of the autovial and was centrifuged at 
5000 g rpm for 5 minutes. This step was repeated three times to allow all the fluid 
to pass through the disk into the autovial insert containing all the peptides. For 
removing all the liquid, the STAGE tip was discarded and the collection tubes 
with autovial inserts containing peptide samples were placed into the Speed Vac 
(Thermo Speed Vac Concentrator DNA 120), to vacuum-centrifuge. Then, the 
autovial inserts were removed from the Speed Vac and the springs were attached 
back to the bottom of the inserts, before placing them into the autovials. Samples 
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were prepared by adding 25 μl of MS Loading Solvent-A (2% Acetonitrile +0.1% 
Trifluoroacetic acid) into each autovial inserts with samples ready to be injected 
and analysed on mass spectrometer.
2.6  Proteomic data of A1 and A2 HFAs using liquid chromatography – mass 
spectrometry (LC/MS/ MS) technique
The process of LC/MS/MS technique was optimised with multiple steps using 
different procedures. The first step of optimisation was the technique used to 
extract the protein from A1 and A2 HFAs. The following steps were taken to 
improve the protein extraction from the astrocytes, after analysing the chromato-
grams (Figures 4 and 5), obtained from the proteomics laboratory, UTS.
i. Clumping of the peptide-peaks was observed due to the effect of surfactant-
like substances, as shown in Figure 4. Therefore, 1% sodium deoxycholate 
(SDC) was used as lysis buffer, instead of reconstitution buffer.
ii. The number of astrocytes for extraction of the proteins was increased from 
1x 106 to 1x 107.
The optimisation of protein-elution in relation to the retention time was 
observed in the following Figures 4 and 5.
Figure 3. 
Shows a 2 ml pipette-tip (STAGE tip) inserted through a hole drilled into the top of a 2 ml collection tube. 
The pipette tip with SDB-RPS disk was inserted into the Eppendorf tube through the hole. Cell solution was 
pipetted from the top into tip so peptides could react with the SDB-RPS disk for 10 minutes.
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2.6.1 PEAKS software
PEAKS (Bioinformatics Solutions Inc.) software was used for the data analysis 
of the proteins detected from LC–MS–MS, by integrating the area under the 
curve (Figure 6) and statistical comparison of the initial data (Figure 7), using 
Student’s dependent t-test as mentioned below. Triplicates of each set of A1 and 
A2 samples (n = 9) were carefully analysed using either one of the two filters:
Figure 5. 
Panels A, B and C with the same descriptions as for Figure 4, except displaying greater retention of protein 
spikes, because of the optimization of protein extraction method. Panel D, indicates mass-to-charge ratio 
(m/z), used for the standardisation of other graphs.
Figure 4. 
There were 4 panels in this first set of chromatograms obtained after LC–MS analysis of A1 and A2 astrocytes. 
Panel A, shows the retention time against frequency of the peptide-peaks, which were clumped together due 
to surfactant-like substances. Panel B, shows the relative abundance of peptide-spikes against time. Panel 
C, displays the expanded version of panel B. panel D, indicates mass-to-charge ratio (m/z), used for the 
standardisation of the other graphs.
11
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i. Peaks Peptide Score (-10lgP) threshold, only peptides with a score above 
this threshold were used to quantify the identified proteins, separating low 
scoring proteins as unique peptide count.
ii. False discovery rate (FDR) threshold (1%).
2.7 Statistical analysis
All values in this text are expressed as mean ± standard error mean (SEM). 
Differences between two groups were determined using Student’s paired dependent 
t-test and were considered significant at P < 0.05. All statistical analyses were conducted 
using Microsoft Excel and GraphPad Prism version 8.0.1, GraphPad Software. Light 
microscopic micrographs were obtained on a Leica Microsystems, LAS version 4.4.0.
3. Results
3.1 A1 (reactive) and A2 (normal) HFAs in culture
The results show that the HFAs increase in size and number with increasing time in 
tissue culture. Distinct differences were observed in the morphology of the cells pres-
ent in A1 and A2 flasks, for example A1 astrocytes have more fibroblast-like structures 
as compared to A2 astrocytes, which look more like neurons (Figure 7). A noticeable 
difference was observed in the thickness of the processes between the two types of the 
HFAs. This thickening was due to the accumulation of filament proteins such as glial 
fibrillary acidic proteins (GFAP) as shown in Figure 8. Whereas Figure 9 shows the 
astrocytes present in the spontaneously hypertensive rat (SHR) and normal Wistar 
Kyoto (WKY) rat brain slices. Figure 9, shows the similarities between A1 HFAs and 
the SHR astrocytes, implying that the A1 HFAs mimic the hypertensive condition.
3.2 Identification of proteins in A1 and A2 HFAs, using LC/MS/MS technique
The present study was focused on specific proteins, such as glial fibrillary acidic 
protein (GFAP), calpain, calpastatin, cathepsin and mitogen activated protein 
kinase (MAPK).
Figure 6. 
Experimental error chart, indicating the minimal error (1%) in peptides-spectrum matches (PSMS) against 
part per million (ppm), using PEAKS software.
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3.2.1 GFAP
The GFAP protein is an indicator of HFAs reactivity, therefore, it was important 
to carefully measure the area under the curve to determine its degree of intensity. For 
comparative analysis, the peaks closest to the center of the peptides-spectrum matches 
(PSMS) were selected, against part per million (ppm) as shown above in Figure 6.
The elevated level of GFAP in A1 cells (4.39 ± 0.4) was observed, compared to 
A2 cells (3.02 ± 0.3), as shown in Figure 9. A significantly higher level of GFAP 
(P < 0.05) in A1 compared to A2, resulted in the thickening of processes (indicated 
by arrows in Figures 7, 9 and 10 above).
Protein molecules such as calpain, calpastatin, cathepsin and mitogen 
activated protein kinase (MAPK) are known to be activated by intracellular 
calcium, leading to their relevant cell signalling cycles and in turn gene [24] 
modifications.
Figure 8. 
Panel A, shows the normal astrocytes in WKY rat brain slices. Panel B, displays the reactive astrocytes in 
SHR brain slices. Arrows indicate the upregulation of intermediate filament proteins in SHR astrocytes. Panel 
C, shows the difference between the intensity of GFAP in the astrocytes of normal and hypertensive rats. 
***P < 0.001, scale bar, 20 μm.
Figure 7. 
Shows normal HFAs in two flasks, labelled A1 and A2. Panel A and B display 2 and 10 days old normal HFAs, 
respectively. Panel C, represents 18 days old normal (A2) and ATP-treated reactive (A1) astrocytes, arrows 
indicating the thickening of the internal filaments. Scale bar, 100 μm.
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3.2.2 Calpain
The results show a significantly higher level (Figure 11) of Calpain in A1 
(6.37 ± 0.6) compared to A2 (3.40 ± 0.2), indicating a greater level of calpain lead-
ing to cytotoxicity in reactive HFAs.
3.2.3 Calpastatin
The results indicate that reactive astrocytes A1 (5.52 ± 0.5) have significantly 
higher levels of calpastatin as compared to the normal A2 (4.09 ± 0.6) astrocytes 
Figure 9. 
Level of glial fibrillary acidic protein (GFAP) in normal and reactive astrocytes. Area under the curve (AUC) 
values are shown as means ± SEM, *P < 0.05, (n = 9).
Figure 10. 
Panel A (reactive) and panel B (normal) show HFAs after 10 days in culture. Panel C (reactive) and panel D 
(normal) is after 18 days in culture. Arrows indicate the difference in the thickening of internal filaments, i.e., 
on day 10 it was 2.5 μm as compared to 4.5 μm on day 18. Scale bar, 10 μm.
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(Figure 12). Calpastatin is the most specific endogenous calpain-inhibitor, which 
binds to the active sites of calpain to prevent its activation [25].
3.2.4 Cathepsin
A highly significant increase was observed in the levels of cathepsin in A1 
(6.31 ± 0.7) compared to A2 (3.86 ± 0.4) cells (Figure 13). Both types of HFAs 
display human specific cathepsin.
3.2.5 Mitogen activated protein kinase (MAPK)
SP3 Proteomic results show a significantly higher level of MAPK enzyme in A1 
(6.31 ± 0.7) compared to A2 (3.72 ± 0.4) HFAs (Figure 14). This kinase is an essen-
tial component of the cell signalling pathway, responsible for the communication 
between a receptor on the cell-surface to the DNA inside the nucleus [6, 26].
Figure 12. 
Level of calpastatin in normal and reactive astrocytes. Area under the curve (AUC) values are shown as means 
± SEM, **P < 0.01, (n = 9).
Figure 11. 
Level of calpain in normal and reactive astrocytes. Area under the curve (AUC) values are shown as means ± 
SEM, ***P < 0.001, (n = 9).
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All the above-mentioned proteins were identified in both A1 and A2 HFAs, using 
immunocytochemistry and proteomics (SP3) protocols. Higher levels of calcium-
gated proteins in A1 are potential biomarkers of HTN.
4. Discussion
This study demonstrated for the first time that reactive astrocytes in HFAs 
mimic hypertensive conditions. The present research indicates that the reactive 
(A1) HFAs have a similar protein profile to astrocytes of hypertensive rats. ATP was 
used in these experiments to mimic endogenous conditions, as it is released from 
the damaged cells following tissue injury [27, 28].
The proteins selected as predictive biomarkers for HTN, are either responsible 
for the reactivity of the astrocytes, or produced because of the interaction between 
Figure 13. 
Level of cathepsin in normal and reactive astrocytes. Area under the curve (AUC) values are shown as  
means ± SEM, ***P < 0.001, (n = 9).
Figure 14. 
Level of MAPK in normal and reactive astrocytes. Area under the curve (AUC) values are shown as  
means ± SEM, ***P < 0.001, (n = 9).
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orexin and NMDA receptors. Most of the proteins selected as predictive biomarkers 
were calcium binding proteases. The results from A1 and A2 HFAs show that calcium 
dependent proteins, such as GFAP, calpain, calpastatin, cathepsin and mitogen acti-
vated protein kinase (MAPK) were present at higher concentrations in reactive (A1) 
than in non-reactive (A2) astrocytes. These results suggest that the above-mentioned 
proteins may be targeted as therapeutic agents for the prevention of HTN.
Immunocytochemistry, in conjunction with the confocal microscopy were used 
to assess and visualise the proteins, such as internal filament proteins in HFAs. 
Mass spectrometry (LC/MS/MS) was used to validate the results, obtained by using 
immunocytochemistry. The SP3 proteomic protocol was employed to identify and 
estimate the protein-peptide molecules.
Reactive astrocytes (A1) were prepared from the normal (A2) HFAs, by using 
ATP (Figure 7), as described earlier in primary cell lines of neonatal rats [29]. In 
contrast, a recent research [23] reported that ATP was not sufficient to induce a 
complete reactive phenotype of astrocytes, in vitro. This discrepancy between the 
two results may be because HFAs were used in the current study, whereas Adzic et 
al. [23] used mature astrocytes obtained from the rats. This concept was further 
verified by the micrographs from light microscopy (Figure 7) and confocal 
microscopy (Figures 8 and 10) which showed a gradual increase in the conflu-
ency as well as in the thickness of the processes of the HFAs with increasing time 
in culture. Hence, our experiments confirmed that the reactivity profile of the 
astrocytes changed as they developed. This proliferation of the filaments is due 
to an increase in the accumulation of GFAP with time [30]. In A1 astrocytes, the 
thickness of the processes on day 10 was 2.5 μm as compared to 4.5 μm on day 18 
(Figures 7 and 10), indicating that there was a periodic increase in the concentra-
tion of GFAP in the reactive astrocytes. This significant thickening of astrocytic 
processes in A1 HFAs (Figure 8), was like that observed in the astrocytes of 
hypertensive rats (Figure 9). SP3 proteomic result for GFAP (Figure 9) was simi-
lar to the microscopic result, representing a significant increase of GFAP in reac-
tive as compared to normal astrocytes. These results of the protein analysis were 
similar to the study by Hol et al. [31], indicating that an upregulation of GFAP 
in reactive astrocytes, coincides with neurodegenerative diseases such as HTN. 
Similarly, a previous study [32] has established that increased levels of GFAP was 
directly related to hypertension, in SHRs. Hence, based on the literature and our 
study results, it can be concluded that the reactivity in astrocytes could be a direct 
indicator of hypertension.
The results of our study showed that A1 has both increased levels of GFAP (Figure 
9) and calpain (Figure 11), indicating the increased reactivity in A1 astrocytes may be 
due to the higher level of calpain, as shown in the previous studies [33, 34], resulting 
in atherosclerosis and hence HTN [35]. Other studies [36] indicate that calpain can 
also act on the extracellular substrates, such as collagen-fibronectin, to modulate the 
cell activity. As calpain can act both intra and extracellularly, it could be a therapeutic 
target for the prevention of cardiovascular diseases, including hypertension.
In contrast, calpastatin, an endogenous inhibitor of calpain, attenuates its cyto-
toxicity, thus increasing the levels of calpastatin may be beneficial in the regulation 
of HTN [25]. The current results show lower expression of calpastatin (Figure 12) 
as compared to calpain (Figure 11) in A1 astrocytes, indicating a decreased level of 
calpastatin in reactive HFAs. These results also suggest that an additional amount 
of exogenous calpastatin may decrease the toxic activity of calpain, by blocking the 
active sites of calpain [37]. This remarkable role of calpastatin makes it a promising 
therapeutic agent for managing blood pressure.
Likewise, another endogenous protease cathepsin, which is involved in inflam-
matory disorders, was found to be significantly higher (Figure 13) in reactive 
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(A1) astrocytes. Evidence suggests that cathepsin plays an important role in HTN 
through vascular modulation [38], leading to atherosclerosis. It has also been 
reported that cathepsin regulates the phosphorylation of mitogen activated protein 
kinase- kinase (MEK) in Angiotensin II-dependent hypertension [39]. Angiotensin 
II induces g-protein regulated MAPK cell signalling cycle [40], therefore MAPK 
was measured in both A1 and A2 astrocytes (Figure 14), and it was found to be 
significantly higher in A1 as compared to A2. This augmented level of MAPK in 
A1 HFAs could be responsible for the thickening of their intermediate filaments 
(Figure 10), as indicated previously in another study [41] that MAPK upregulates 
cell proliferation.
In a recent study, the phosphorylation of MAPK in the arteries of hypertensive 
patients as well as in a mice model [39] was observed. Moreover, the proliferation of 
arterial smooth muscle cells in both, human and mice models were detected. Thus, a 
vascular modulatory role of MAPK, which is related to HTN, was confirmed.
Our initial findings based on immunocytochemistry and SP3 proteomic results 
indicate that identifying molecules such as calpain, calpastatin, cathepsin and 
MAPK may be useful in reducing the reactivity in the astrocytes, which is an 
indicator of HTN. The present study shows that in A1, there is an increased levels 
of calcium gated proteins, possibly due to higher concentration of the intracellular 
calcium [42, 43], leading to hypertension.
Protein-based therapeutic agents have been highly successful in clinics [44]. 
More than hundred original and modified therapeutic proteins are used up till now. 
There are at least five ways of utilising proteins as therapeutic agents:
a. replacing damaged proteins [45]
b. augmenting the effects of weak proteins [46]
c. interfering with an intermediate molecule or its function [47]
d. providing synthetic molecules for normal function [48]
e. delivering other compounds or proteins [49]
Further experiments are needed to test these enzymes, using ELISA kits for the 
specific regulatory proteins, such as S100B, soluble receptor for advanced glyca-
tion end product (sRAGE) and GFAP, to identify the most promising predictive 
biomarker for HTN. The highly specific indicator of astrocytic reactivity, GFAP 
[50], was measured earlier by immunocytochemistry, proteomics, and now ELISA 
protocol will be used for further quantification of cytotoxicity due to the higher 
concentration of GFAP in the reactive astrocytes.
Similarly, the Ca2+-binding protein S100B, acts both intra and extracellularly 
in HFAs. Inside the cell, S100B acts as a stimulator of proliferation and activation 
of astrocytes. Whereas, extracellularly, S100B engages sRAGE in pro-proliferative 
activities [51]. Though, sRAGE might not be the only S100B receptor, and S100B’s 
ability to engage sRAGE might be regulated by its interaction with other calcium-
binding proteases, such as calpain, calpastatin, cathepsin and MAPK.
5. Conclusion
This study shows for the first time that reactive astrocytes in HFAs mimic 
hypertensive conditions, and calcium-dependent proteins such as GFAP, calpain, 
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calpastatin, cathepsin and MAPK could be considered as potential predictive 
biomarkers for HTN.
6. Future plans
More experiments are needed for the validation of the predictive biomarkers for 
HTN. We need to further characterise proteins (S100B, sRAGE and GFAP) in both 
types of HFAs, using ELISA technique.
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